Alaunos Therapeutics
TCRT
142 hedge funds and large institutions have $354M invested in Alaunos Therapeutics in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 32 reducing their positions, and 20 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 32
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
1% more funds holding
Funds holding: 140 → 142 (+2)
0.05% more ownership
Funds ownership: 0.29% → 0.34% (+0.05%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less capital invested
Capital invested by funds: $409M → $354M (-$55.3M)
36% less call options, than puts
Call options by funds: $6.68M | Put options by funds: $10.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
+$22M |
| 2 |
MVP
Miller Value Partners
Sarasota,
Florida
|
+$19.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.3M |
| 4 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$7.61M |
| 5 |
BlackRock
New York
|
+$2.81M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$2.6M |
| 2 |
SG Americas Securities
New York
|
-$2.21M |
| 3 |
D.E. Shaw & Co
New York
|
-$1.29M |
| 4 |
Barclays
London,
United Kingdom
|
-$589K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$564K |
TCRT Hedge Fund Activity: Q3 2019 in Review
142 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2019, worth a combined $354M — down 14% from $409M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TCRT positions and 20 closed out — a net gain of 2 holders — while 48 added to existing stakes and 32 trimmed.
The largest buyer was MSD Partners, adding an estimated $22M. The largest seller was Invesco, exiting entirely with an estimated $2.6M sold.
- 142 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2019, up from 140 in Q2 2019.
- Funds reported $354M of Alaunos Therapeutics stock for Q3 2019, down 14% quarter-over-quarter.
- 22 funds opened new Alaunos Therapeutics positions in Q3 2019 and 20 closed out, a net change of +2 holders.
- The largest Alaunos Therapeutics buyer in Q3 2019 was MSD Partners, an estimated $22M added.
- The largest Alaunos Therapeutics seller in Q3 2019 was Invesco, an estimated $2.6M sold.
Based on aggregated 13F filings for Q3 2019.